Loading...

Immutep Limited

IMM.AXASX
Healthcare
Biotechnology
A$0.26
A$0.01(4.08%)

Immutep Limited (IMM.AX) Financial Performance & Income Statement Overview

Access detailed quarterly and annual financial reports for Immutep Limited (IMM.AX), covering cash flow, earnings, and balance sheets.

Revenue Growth
9.59%
9.59%
Operating Income Growth
-96.06%
96.06%
Net Income Growth
-7.07%
7.07%
Operating Cash Flow Growth
2.96%
2.96%
Operating Margin
-1973.50%
1973.50%
Gross Margin
-851.85%
851.85%
Net Profit Margin
-899.06%
899.06%
ROE
-24.24%
24.24%
ROIC
-55.62%
55.62%

Immutep Limited (IMM.AX) Income Statement & Financial Overview

Explore comprehensive income reports for Immutep Limited IMM.AX, broken down by year and quarter.

MetricQ2 2025Q4 2024Q2 2024Q4 2022
Revenue$3.15M$1.73M$2.11M$1.82M
Cost of Revenue$25.33M$21.11M$20.44M$924019.00
Gross Profit-$22.18M-$19.38M-$18.33M$896169.00
Gross Profit Ratio-$7.05-$11.20-$8.68$0.49
R&D Expenses$25.33M$21.11M$20.44M$9.82M
SG&A Expenses$4.23M$4.05M$4.80M$20.91M
Operating Expenses$29.56M$25.16M$25.24M$20.91M
Total Costs & Expenses$54.90M$46.27M$45.67M$21.83M
Interest Income$3.14M$1.88M$2.00M$635310.00
Interest Expense$0.00$0.00$0.00$5414.00
Depreciation & Amortization$23477.00$1.08M$929607.00$924019.00
EBITDA-$26.39M-$22.35M-$22.20M-$20.91M
EBITDA Ratio-$8.38-$12.91-$10.52-$11.49
Operating Income-$51.75M-$44.54M-$43.56M-$21.83M
Operating Income Ratio-$16.44-$25.73-$20.64-$11.99
Other Income/Expenses (Net)$29.37M$23.05M$22.34M$2.56M
Income Before Tax-$22.38M-$21.49M-$21.23M-$19.27M
Income Before Tax Ratio-$7.11-$12.41-$10.06-$10.59
Income Tax Expense$0.00$0.00$0.00$1.00
Net Income-$22.38M-$21.49M-$21.23M-$19.27M
Net Income Ratio-$7.11-$12.41-$10.06-$10.59
EPS-$0.02-$0.02-$0.02-$0.02
Diluted EPS-$0.02-$0.02-$0.02-$0.02
Weighted Avg Shares Outstanding$1.45B$1.21B$1.19B$873.28M
Weighted Avg Shares Outstanding (Diluted)$1.45B$1.22B$1.19B$913.12M

Over the last four quarters, Immutep Limited achieved steady financial progress, growing revenue from $1.82M in Q4 2022 to $3.15M in Q2 2025. Gross profit stayed firm with margins at -705% in Q2 2025 versus 49% in Q4 2022. Operating income totaled -$51.75M in Q2 2025, maintaining a -1644% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$26.39M. Net income dropped to -$22.38M, with EPS at -$0.02. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;